Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
Year: 2026
Type: article
Study design: Case Report
Abstract: The efficacy of epcoritamab in refractory diffuse large B-cell lymphoma (DLBCL) has been established. However, its safety in dialysis-dependent patients is unclear. A 53-year-old man with refractory DLBCL who had received a series of different chemotherapies became dependent on dialysis because of worsening preexisting chronic kidney disease. Epcoritamab was initiated at a standard dose, and a complete response was achieved after the third cycle. However, it was discontinued after the seventh cycle because of the development of lower leg necrosis due to pre-existing arteriosclerosis. Epcoritamab may therefore be feasible with careful monitoring, even in dialysis-dependent patients with refractory DLBCL.
Source: Internal Medicine
Authors: Yuya Sasaki, Keisuke Tanaka, Hisako Nakamaki, Makiko Ogawa, Yoshihiro Umezawa, Masahide Yamamoto, Takehiko Mori
Institution: Institute of Science Tokyo Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7169517468